These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 3230330)

  • 1. Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days.
    Dorr RT; Salmon SE; Robertone A; Bonnem E
    J Interferon Res; 1988 Dec; 8(6):717-25. PubMed ID: 3230330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer.
    Iacobelli S; Garufi C; Irtelli L; Martino MT; Santobuono F; Vicario G; Tinari N; Fiorentino B; Innocenti P; Natoli C
    Am J Clin Oncol; 1995 Feb; 18(1):27-31. PubMed ID: 7847255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I trial of 21-day continuous venous infusion of alpha-interferon at circadian rhythm modulated rate in cancer patients.
    Deprés-Brummer P; Levi F; Di Palma M; Beliard A; Lebon P; Marion S; Jasmin C; Misset JL
    J Immunother (1991); 1991 Dec; 10(6):440-7. PubMed ID: 1768678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Home therapy with recombinant interleukin-2 and interferon-alpha 2b in advanced human malignancies.
    Atzpodien J; Körfer A; Franks CR; Poliwoda H; Kirchner H
    Lancet; 1990 Jun; 335(8704):1509-12. PubMed ID: 1972442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study combining tumor necrosis factor with interferon-alpha and interleukin-2.
    Eskander ED; Harvey HA; Givant E; Lipton A
    Am J Clin Oncol; 1997 Oct; 20(5):511-4. PubMed ID: 9345339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved tolerance of interferon alpha-2a by continuous subcutaneous infusion.
    Ludwig CU; Ludwig-Hagemann R; Obrist R; Obrecht JP; Holdener EE; Sutter-Melde C
    Onkologie; 1990 Apr; 13(2):117-22. PubMed ID: 2197582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
    Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of interferon alpha-2b with folinic acid and 5-fluorouracil administered by 4-hour infusion in metastatic colorectal carcinoma.
    Kreuser ED; Hilgenfeld RU; Matthias M; Hoksch B; Boewer C; Oldenkott B; Knauf WU; Boese-Landgraf J; Schalhorn A; Zeitz M
    Semin Oncol; 1992 Apr; 19(2 Suppl 3):197-203. PubMed ID: 1557647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of recombinant alpha-2b interferon in the treatment of metastatic skin melanoma.
    Sertoli MR; Bernengo MG; Ardizzoni A; Brunetti I; Falcone A; Vidili MG; Cusimano MP; Appino A; Doveil G; Fortini C
    Oncology; 1989; 46(2):96-8. PubMed ID: 2710482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interferon-alpha-2b treatment of hairy-cell leukaemia: experience with a low-dose schedule.
    Hasselbalch H; Braide I; Lisse I; Röckert LL; Swolin B; Carneskog J; Hagberg H; Hippe E; Jensen MK; Lundin P
    Eur J Haematol; 1988 Nov; 41(5):438-44. PubMed ID: 3061836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I study of escalating dose mitoxantrone in combination with alpha-2-interferon in patients with advanced solid tumors.
    Gasparini G; Dal Fior S; Pozza F; Panizzoni GA; Favretto S; Von Hoff DD
    Invest New Drugs; 1991 Aug; 9(3):245-52. PubMed ID: 1783524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant interferon alpha-2b in the treatment of diffuse malignant pleural mesothelioma.
    Ardizzoni A; Pennucci MC; Castagneto B; Mariani GL; Cinquegrana A; Magri D; Verna A; Salvati F; Rosso R
    Am J Clin Oncol; 1994 Feb; 17(1):80-2. PubMed ID: 8311014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escalating doses of interferon alpha-2A with cisplatin and concomitant radiotherapy: a phase I study.
    Vokes EE; Haraf DJ; Hoffman PC
    Cancer Chemother Pharmacol; 1993; 33(3):203-9. PubMed ID: 8269601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant alpha-interferon and vinblastine in metastatic renal cell carcinoma: efficacy of low doses.
    Cetto GL; Franceschi T; Turrina G; Chiarion-Sileni V; Capelli MC; Bellini A; Paccagnella A; Bassetto MA; Molino AM; de Sandre G
    Semin Surg Oncol; 1988; 4(3):184-90. PubMed ID: 3055162
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b.
    Tsavaris N; Baxevanis C; Kosmidis P; Papamichael M
    Cancer Immunol Immunother; 1996 Oct; 43(2):94-102. PubMed ID: 8954143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Continuous-infusion floxuridine and alpha interferon in metastatic renal cancer: a national biotherapy study group phase II study.
    Soori GS; Schulof RS; Stark JJ; Wiemann MC; Honeycutt PJ; Church CK; DePriest CB
    Cancer Invest; 1999; 17(6):379-84. PubMed ID: 10434947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraperitoneal human recombinant interferon alpha-2b in minimal residual ovarian cancer.
    Willemse PH; de Vries EG; Mulder NH; Aalders JG; Bouma J; Sleijfer DT
    Eur J Cancer; 1990 Mar; 26(3):353-8. PubMed ID: 2141493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.